These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
514 related items for PubMed ID: 11921648
1. [Hormone replacement therapy in peri- and postmenopause. Routine use is not indicated]. Emons G, Westphalen S. MMW Fortschr Med; 2002 Feb 28; 144(9):30-3. PubMed ID: 11921648 [Abstract] [Full Text] [Related]
2. [Which is the better choice, estrogen or SERMs in postmenopausal women?]. Shintani M. Clin Calcium; 2004 Oct 28; 14(10):105-10. PubMed ID: 15577140 [Abstract] [Full Text] [Related]
4. Hormone replacement therapy in postmenopausal women. Yasui T, Uemura H, Takikawa M, Irahara M. J Med Invest; 2003 Aug 28; 50(3-4):136-45. PubMed ID: 13678382 [Abstract] [Full Text] [Related]
5. [Hormone replacement therapy and cancer]. Bjørge T, Tropé C. Tidsskr Nor Laegeforen; 1997 Jun 10; 117(15):2201-7. PubMed ID: 9235712 [Abstract] [Full Text] [Related]
6. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women. Lee WL, Chao HT, Cheng MH, Wang PH. Maturitas; 2008 Jun 20; 60(2):92-107. PubMed ID: 18534794 [Abstract] [Full Text] [Related]
7. Raloxifene. Not better than estrogen. Can Fam Physician; 2000 Aug 20; 46():1592-6, 1599-603. PubMed ID: 10955178 [Abstract] [Full Text] [Related]
8. Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003. Burger H. Climacteric; 2003 May 20; 6 Suppl 1():11-36. PubMed ID: 12945798 [Abstract] [Full Text] [Related]
9. [Estrogen replacement therapy: for whom, why and how?]. Rozenberg S, Neusy S, Barudy J, Fellemans C, Jahjah L. Rev Med Brux; 2002 Sep 20; 23(4):A382-9. PubMed ID: 12422465 [Abstract] [Full Text] [Related]
10. [Cardiovascular effects of selective estrogen receptor modulators. Current perspectives]. Simoncini T, Mannella P, Genazzani AR. Recenti Prog Med; 2003 Feb 20; 94(2):51-6. PubMed ID: 12908369 [Abstract] [Full Text] [Related]
11. Hormone replacement therapy in postmenopausal women. Prelevic GM, Kocjan T, Markou A. Minerva Endocrinol; 2005 Mar 20; 30(1):27-36. PubMed ID: 15877011 [Abstract] [Full Text] [Related]
12. Breast cancer risk in the WHI study: the problem of obesity. Kuhl H. Maturitas; 2005 May 16; 51(1):83-97. PubMed ID: 15883113 [Abstract] [Full Text] [Related]
13. [Hormonal replacement therapy and selective estrogen receptor modulators in prevention of cardiovascular disease]. Kozakiewicz K, Wycisk A. Wiad Lek; 2006 May 16; 59(5-6):377-82. PubMed ID: 17017486 [Abstract] [Full Text] [Related]
14. [Effects of SERM on breast cancer and cardiovascular disease: making a comparison between raloxifene use and hormone replacement therapy on the risks of the diseases]. Higuchi T, Mizunuma H. Clin Calcium; 2004 Oct 16; 14(10):81-4. PubMed ID: 15577136 [Abstract] [Full Text] [Related]
15. Raloxifene: new preparation. Not better than oestrogen. Prescrire Int; 1999 Dec 16; 8(44):165-7. PubMed ID: 11503811 [Abstract] [Full Text] [Related]
16. HRT dosing regimens: continuous versus cyclic-pros and cons. Shoupe D. Int J Fertil Womens Med; 2001 Dec 16; 46(1):7-15. PubMed ID: 11294619 [Abstract] [Full Text] [Related]
17. [An alternative to postmenopausal Hormone Replacement Therapy? Selective Estrogens Receptors Modulators (SERMs)]. Tinelli A, Perrone A, Tinelli FG. Minerva Ginecol; 2001 Apr 16; 53(2):127-35. PubMed ID: 11319506 [Abstract] [Full Text] [Related]
19. [Present position of the hormonal replacement therapy]. Fait T, Vokrouhlická J, Vrablík M, Jenícek J. Cas Lek Cesk; 2004 Apr 16; 143(7):447-52. PubMed ID: 15373286 [Abstract] [Full Text] [Related]
20. Hormone replacement therapy--is there a place for its use in neurology? Vuković V, Lovrencić-Huzjan A, Solter VV, Dordević V, Demarin V. Coll Antropol; 2003 Jun 16; 27(1):413-24. PubMed ID: 12974172 [Abstract] [Full Text] [Related] Page: [Next] [New Search]